ClinicalTrials.gg
CompletedNCT03418610Updated Jul 24, 2019

Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea

A Phase 4 interventional study of Azelaic Acid foam 15% in Rosacea, Papulopustular, sponsored by Clinical Research Center of the Carolinas. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-24.

Sponsored by Clinical Research Center of the Carolinas · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jan 2019, 7 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 12 studies testing azelaic acid in Rosacea — none open to participants now, none under way, none of them phase 3. azelaic acid · Rosacea.

Enrollment
12th of 12
5 · median 77
Started
2017
with 1 other
Phase 4
5 of 12
none open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
Clinical Research Center of the Carolinas

Among the 12 studies testing azelaic acid in Rosacea, this one is the 12th largest by enrollment, is one of 2 that started in 2017, is one of 5 in phase 4, and was the 11th registered.

Rosacea

235 studies on the registry are indexed under Rosacea; 24 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 12 studies testing azelaic acid in Rosacea is open now. The open studies under Rosacea, anywhere →

Where they have run

About azelaic acid

azelaic acid: first FDA approval 1995 (AZELEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 17 Rosacea studies recruiting now, 10 (59%) set no upper age limit and 6 (35%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing azelaic acid in Rosacea as a file.
02

Study summary

This research study is being performed to evaluate the photographic evidence of the efficacy and tolerability of Azelaic Acid Foam 15% in the treatment of papulopustular rosacea.

Read the detailed description

This is a single site, single arm open label study of Azelaic Acid foam 15% for the treatment of moderate to severe papulopustular rosacea. All patients will apply Azelaic Acid foam twice daily. At scheduled visits, high resolution equipment will be used to measure 3D topographical values for elevation of papules and pustules to objectively evaluate reduction of papulopustular lesions. Investigator and subject assessments will also be completed to assess the level of rosacea at weeks 4,8 and 12.

03

Conditions studied

  • Rosacea, Papulopustular

Browse trials for

Keywords

  • Rosacea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects age 18 or older.
  2. Diagnosis of moderate to severe papulopustular rosacea with IGA of 3- moderate or 4-severe.
  3. Presence of 12 - 50 inflammatory lesions and persistent erythema with or without telangiectasia.
  4. Subjects must read, understand, and sign the .
  5. Subjects must be willing and able to comply with study procedures and visit schedule requirements.
  6. Women of that are willing to use an acceptable method of during the study.

Exclusion criteria

Exclusion Criteria:

  1. Active or localized or systemic infections.
  2. Subjects must not be .
  3. Known unresponsiveness or allergy to azelaic acid.
  4. Subjects unlikely to comply with the protocol, e.g. mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the clinical study, uncooperative attitude or unlikelihood of completing the study (e.g. drug or alcohol abuse).
  5. Subjects must not be pregnant or breastfeeding.
  6. Presence of dermatoses that might interfere with the ability to diagnose and/or evaluate rosacea.
  7. Presence of other types of rosacea.
  8. Laser surgery on the face for the treatment of telangiectasia or other conditions within 6 weeks of study enrollment.
  9. Use of medications or products for the treatment of rosacea or other medical conditions within the following time periods prior to study enrollment. Use of these medications will be prohibited during the trial.

    Topical Prescription or Nonprescription medications 6 weeks Oral retinoids 6 months Tetracycline (ex. doxycycline, minocycline 2 months 4 weeks Erythromycin or azithromycin 4 weeks Other systemic medications to treat rosacea 6 weeks

  10. Refusal to sign the document or Photo Release document and/or refusal to comply with all follow-up requirements.
  11. Use of medications that are known to cause flushing.
  12. Dose changes in the last 90 days or initiation of beta-blockers, vasodilators, vasoconstrictors, nonsteroidal anti-inflammatory drugs, hormone therapy, and/or other drugs known to cause acneform eruptions.

    -

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Other
    Open Label Single Arm

    Azelaic Acid Foam 15% applied twice daily

    Drug: Azelaic Acid foam 15%

Interventions

06

What researchers measure

Primary outcomes

  1. Inflammatory Lesion Count

    The change in inflammatory lesion counts at week 12 compared to baseline

    Time frame: 12 weeks

Secondary outcomes

  1. Investigator Global Assessment

    Severity of Disease by Investigator Global Assessment, Score of 0 (Clear) - 4(Severe)

    Time frame: 12 weeks

07

Study locations

1 site
  • Clinical Research Center of the Carolinas
    Charleston, South Carolina 29407, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Jan 2019, 13 months.

Of 12 phase 4 interventional studies under Rosacea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 21. This study's 13 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2017
First posted
Feb 1, 2018
StartActual
Dec 6, 2017
Primary completionActual
Jan 9, 2019
CompletionActual
Jan 9, 2019
Last update
Jul 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03418610
Lead sponsor
Clinical Research Center of the Carolinas
Collaborators
Bayer
Responsible party
Sponsor
First posted
Feb 1, 2018
Start date
Dec 6, 2017
Primary completion
Jan 9, 2019
Completion
Jan 9, 2019
Last update
Jul 24, 2019

Study contacts

Todd Schlesinger, MD, FAAD
principal investigator · Medical Director

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azelaic acid

Start the discussion